Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine + Cisplatin +/- Endostar in Resected Stage IB-IIIA NSCLC
NCT00576914Phase 3Unknown
- Sponsor
- Chinese Academy of Sciences
- Start
- Jun 2007
- Primary completion
- Jun 2012
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of endostar in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chinese Academy of Sciences. Primary endpoint: Overall Survival at 5 years. Status: unknown.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00576914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00576914.